JPWO2020132269A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020132269A5
JPWO2020132269A5 JP2021531985A JP2021531985A JPWO2020132269A5 JP WO2020132269 A5 JPWO2020132269 A5 JP WO2020132269A5 JP 2021531985 A JP2021531985 A JP 2021531985A JP 2021531985 A JP2021531985 A JP 2021531985A JP WO2020132269 A5 JPWO2020132269 A5 JP WO2020132269A5
Authority
JP
Japan
Prior art keywords
optionally substituted
trifluoromethyl
pyrazolo
pyrimidine
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021531985A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511515A (ja
JP2022511515A5 (https=
JP7662519B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/067521 external-priority patent/WO2020132269A1/en
Publication of JP2022511515A publication Critical patent/JP2022511515A/ja
Publication of JP2022511515A5 publication Critical patent/JP2022511515A5/ja
Publication of JPWO2020132269A5 publication Critical patent/JPWO2020132269A5/ja
Priority to JP2024102890A priority Critical patent/JP2024150464A/ja
Application granted granted Critical
Publication of JP7662519B2 publication Critical patent/JP7662519B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021531985A 2018-12-20 2019-12-19 置換されたピラゾロピリミジン及び置換されたプリンならびにユビキチン特異的プロセシングプロテアーゼ1(usp1)阻害剤としてのそれらの使用 Active JP7662519B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024102890A JP2024150464A (ja) 2018-12-20 2024-06-26 置換されたピラゾロピリミジン及び置換されたプリンならびにユビキチン特異的プロセシングプロテアーゼ1(usp1)阻害剤としてのそれらの使用

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862783014P 2018-12-20 2018-12-20
US62/783,014 2018-12-20
US201962799423P 2019-01-31 2019-01-31
US62/799,423 2019-01-31
US201962857986P 2019-06-06 2019-06-06
US62/857,986 2019-06-06
US201962868616P 2019-06-28 2019-06-28
US62/868,616 2019-06-28
US201962946263P 2019-12-10 2019-12-10
US62/946,263 2019-12-10
PCT/US2019/067521 WO2020132269A1 (en) 2018-12-20 2019-12-19 Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024102890A Division JP2024150464A (ja) 2018-12-20 2024-06-26 置換されたピラゾロピリミジン及び置換されたプリンならびにユビキチン特異的プロセシングプロテアーゼ1(usp1)阻害剤としてのそれらの使用

Publications (4)

Publication Number Publication Date
JP2022511515A JP2022511515A (ja) 2022-01-31
JP2022511515A5 JP2022511515A5 (https=) 2022-12-26
JPWO2020132269A5 true JPWO2020132269A5 (https=) 2022-12-26
JP7662519B2 JP7662519B2 (ja) 2025-04-15

Family

ID=71100912

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021531985A Active JP7662519B2 (ja) 2018-12-20 2019-12-19 置換されたピラゾロピリミジン及び置換されたプリンならびにユビキチン特異的プロセシングプロテアーゼ1(usp1)阻害剤としてのそれらの使用
JP2024102890A Pending JP2024150464A (ja) 2018-12-20 2024-06-26 置換されたピラゾロピリミジン及び置換されたプリンならびにユビキチン特異的プロセシングプロテアーゼ1(usp1)阻害剤としてのそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024102890A Pending JP2024150464A (ja) 2018-12-20 2024-06-26 置換されたピラゾロピリミジン及び置換されたプリンならびにユビキチン特異的プロセシングプロテアーゼ1(usp1)阻害剤としてのそれらの使用

Country Status (16)

Country Link
US (2) US11485736B2 (https=)
EP (1) EP3897652A4 (https=)
JP (2) JP7662519B2 (https=)
KR (1) KR102912147B1 (https=)
CN (1) CN113164485A (https=)
AU (1) AU2019405925B2 (https=)
BR (1) BR112021010715A2 (https=)
CA (1) CA3122108A1 (https=)
CL (1) CL2021001575A1 (https=)
CO (1) CO2021009078A2 (https=)
IL (1) IL284050B2 (https=)
MX (1) MX2021007179A (https=)
PH (1) PH12021551402A1 (https=)
SG (1) SG11202106232TA (https=)
TW (2) TWI895986B (https=)
WO (1) WO2020132269A1 (https=)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10189841B2 (en) 2015-11-20 2019-01-29 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
BR112021010715A2 (pt) 2018-12-20 2021-11-16 Ksq Therapeutics Inc Pirazolopirimidinas substituídas e purinas substituídas e seu uso como inibidores de protease de processamento ubiquitina-específica 1 (usp1)
JP7253640B2 (ja) 2019-01-31 2023-04-06 武田薬品工業株式会社 複素環化合物およびその用途
ES3025474T3 (en) * 2020-01-15 2025-06-09 Ksq Therapeutics Inc Compositions of substituted pyrazolopyrimidines and uses thereof
CA3168009A1 (en) * 2020-02-14 2021-08-19 KSQ Therapeutics, Inc. Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitors
EP4161494A4 (en) * 2020-06-02 2024-07-17 KSQ Therapeutics, Inc. NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS
WO2022053998A1 (en) * 2020-09-10 2022-03-17 Universidade Do Porto New pharmaceutical compounds, methods and uses thereof
KR20230098186A (ko) * 2020-10-30 2023-07-03 케이에스큐 세러퓨틱스 인코포레이티드 치환된 피라졸로피리미딘의 고체 상태 형태 및 이의 용도
US20240182481A1 (en) * 2021-02-15 2024-06-06 Tango Therapeutics, Inc. Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer
AU2022238886A1 (en) * 2021-03-17 2023-09-14 Medivir Ab Purine derivatives as anticancer agents
MX2023011709A (es) * 2021-04-07 2023-10-12 Forma Therapeutics Inc Inhibidor de la proteasa 1 especifica de ubiquitina (usp1).
CN117337290B (zh) * 2021-05-03 2026-01-02 轩竹生物科技股份有限公司 三并环类泛素特异性蛋白酶1抑制剂及其用途
WO2022253188A1 (en) * 2021-05-31 2022-12-08 Impact Therapeutics (Shanghai) , Inc Nitrogen-containing fused heteroaromatic bicyclic compounds as usp1 inhibitors and the use thereof
GB202114863D0 (en) 2021-10-18 2021-12-01 Syngenta Crop Protection Ag Improvements in or relating to organic compounds
JP2024540921A (ja) * 2021-10-19 2024-11-06 上海瑛派▲薬▼▲業▼有限公司 Usp1阻害剤としての置換トリアゾロヘテロアリール化合物及びその応用
CN114031556B (zh) * 2021-11-08 2023-03-31 温州大学 一种绿色的一锅法制备5-氨基-n-芳基-3-芳基吡唑类化合物的合成方法
GEAP202416531A (en) * 2021-11-12 2024-10-28 Insilico Medicine Ip Ltd Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
CR20240191A (es) * 2021-11-12 2024-09-13 Insilico Medicine Ip Ltd Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos
EP4430041A4 (en) * 2021-11-12 2025-09-24 Insilico Medicine Ip Ltd SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) AND THEIR USES
CN114181237B (zh) * 2021-12-01 2024-02-23 上海凌凯医药科技有限公司 一种1-异丙基吡唑-5-硼酸频那醇酯的合成方法
IL312982A (en) * 2021-12-09 2024-07-01 Ksq Therapeutics Inc Methods for the preparation of converted pyrazolopyrimidines
CN118525022A (zh) * 2022-01-27 2024-08-20 西藏海思科制药有限公司 一种氮杂并环衍生物及其在医药上的应用
US20250163049A1 (en) * 2022-02-03 2025-05-22 Exelixis, Inc. Fused bicyclic heterocyclyl compounds as usp1 inhibitors
US20250382289A1 (en) * 2022-02-18 2025-12-18 Xizang Haisco Pharmaceutical Co., Ltd. Pyrazolopyridine derivative and application thereof in medicine
IL315748A (en) * 2022-04-08 2024-11-01 Ksq Therapeutics Inc Therapeutic combinations containing ubiquitin-specific processing protease 1 (USP1) inhibitors and chemotherapy agents
CN116925098B (zh) * 2022-04-09 2026-02-17 深圳湾实验室 靶向泛素特异性蛋白酶1(usp1)的小分子抑制剂及其应用
AU2023261809A1 (en) * 2022-04-29 2024-12-05 Asieris Pharmaceuticals (Shanghai) Co., Ltd. Pyrimidine compound, method for preparing same, and pharmaceutical use thereof
EP4543890A1 (en) * 2022-06-23 2025-04-30 Forma Therapeutics, Inc. Usp1 inhibitors and uses thereof
WO2024006879A1 (en) * 2022-06-29 2024-01-04 Zentaur Therapeutics Usa Inc. Usp1 inhibitors and uses thereof
WO2024022266A1 (en) * 2022-07-25 2024-02-01 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heteroaryl compounds as inhibitors of usp1
WO2024022519A1 (zh) * 2022-07-28 2024-02-01 先声再明医药有限公司 杂环并嘧啶类化合物及其应用
CN119522224A (zh) * 2022-08-09 2025-02-25 上海济煜医药科技有限公司 含氮杂环化合物作为泛素-特异性蛋白酶1抑制剂的制备方法、应用及其用途
CN117263944B (zh) * 2022-08-24 2025-10-17 轩竹生物科技股份有限公司 泛素特异性蛋白酶1抑制剂及其用途
CN119790043A (zh) * 2022-08-26 2025-04-08 海南先声再明医药股份有限公司 三环类化合物及其应用
US20250368667A1 (en) * 2022-09-02 2025-12-04 Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. Usp1 inhibitor
TW202411231A (zh) * 2022-09-09 2024-03-16 大陸商正大天晴藥業集團股份有限公司 用作泛素-特異性蛋白酶抑制劑的取代嘌呤酮衍生物
IL319492A (en) * 2022-09-20 2025-05-01 Chia Tai Tianqing Pharmaceutical Group Co Ltd A carbonyl-fused heterocyclic derivative that acts as a ubiquitin-specific protease
CN117384187B (zh) * 2022-09-30 2026-01-30 轩竹生物科技股份有限公司 泛素特异性蛋白酶1抑制剂
WO2024078436A1 (zh) * 2022-10-09 2024-04-18 海南先声再明医药股份有限公司 杂环并嘧啶类化合物、药物组合物及其应用
WO2024086790A1 (en) 2022-10-21 2024-04-25 Exelixis, Inc. 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-c]PYRIDINE COMPOUNDS AND DERIVATIVES AS USP1 INHIBITORS
WO2024094170A1 (zh) * 2022-11-04 2024-05-10 深圳晶泰科技有限公司 泛素特异性蛋白酶1的抑制剂及其应用
CN120513237A (zh) 2023-01-12 2025-08-19 先正达农作物保护股份公司 除草咪唑化合物
CN120603835A (zh) * 2023-01-20 2025-09-05 杭州英创医药科技有限公司 作为usp1抑制剂的化合物
WO2024222880A1 (zh) * 2023-04-27 2024-10-31 西藏海思科制药有限公司 一种吡啶并吡唑衍生物的药物组合物及其在医药上的应用
WO2024233605A1 (en) 2023-05-08 2024-11-14 Tango Therapeutics, Inc. Compounds and their use against cancer
WO2024233665A1 (en) 2023-05-08 2024-11-14 Tango Therapeutics, Inc. Compounds and their use against cancer
CN116768906B (zh) * 2023-05-29 2024-04-09 遵义医科大学珠海校区 一种三并环化合物及其制备方法和应用
CN121511238A (zh) * 2023-07-05 2026-02-10 江苏亚虹医药科技股份有限公司 嘧啶类化合物、其制备方法及其医药用途
CN121219283A (zh) * 2023-07-05 2025-12-26 江苏亚虹医药科技股份有限公司 联嘧啶化合物的晶型及其制备方法和用途
WO2025010245A1 (en) 2023-07-06 2025-01-09 Exelixis, Inc. Fused pyrazole derivatives as usp1 inhibitors
WO2025015905A1 (en) * 2023-07-14 2025-01-23 Laekna Therapeutics Shanghai Co., Ltd. Pyrimidine compounds and their use as usp1 inhibitors
TW202530229A (zh) * 2023-09-26 2025-08-01 大陸商上海濟煜醫藥科技有限公司 氮雜環胺類化合物作為泛素-特異性蛋白酶1抑制劑的製備方法、應用及其用途
WO2025095751A1 (ko) * 2023-10-30 2025-05-08 현대약품 주식회사 신규한 화합물, 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물
TW202535865A (zh) 2023-10-31 2025-09-16 美商必治妥美雅史谷比公司 泛素特異性加工蛋白酶1 (usp1) 化合物
WO2025096487A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096488A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025102016A1 (en) 2023-11-10 2025-05-15 Vrise Therapeutics, Inc. Novel molecules as inhibitors of dna damage repair pathway
WO2025151705A1 (en) 2024-01-10 2025-07-17 Vrise Therapeutics, Inc. Novel inhibitors of dna damage repair pathway
WO2025180502A1 (zh) * 2024-03-01 2025-09-04 上海齐鲁制药研究中心有限公司 一种联合用药物组合物及其用途
KR20250138136A (ko) * 2024-03-12 2025-09-19 현대약품 주식회사 신규한 화합물, 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
EP0786469B1 (en) 1990-06-11 2006-03-01 Gilead Sciences, Inc. Methods of use of nucleic acid ligands
AU672790B2 (en) 1992-07-15 1996-10-17 Novartis Ag Variants of parathyroid hormone and its fragments
AU3204895A (en) 1995-02-01 1996-08-21 University Of Massachusetts Medical Center Methods of selecting a random peptide that binds to a target protein
EP0934526B1 (en) 1996-10-08 2003-01-08 U-BISys B.V. Methods and means for selecting peptides and proteins having specific affinity for a target
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US9512125B2 (en) * 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
WO2007149484A2 (en) 2006-06-20 2007-12-27 Dana-Farber Cancer Institute Inhibitors of usp1 deubiquitinating enzyme complex
AU2007325900A1 (en) 2006-10-20 2008-06-05 Dnar, Inc. DNA damage repair inhibitors and methods for treating cancer
US7964356B2 (en) 2007-01-16 2011-06-21 Somalogic, Inc. Method for generating aptamers with improved off-rates
BRPI0817503B8 (pt) * 2007-10-05 2021-05-25 Sstarbio Pte Ltd derivados de purina substituídos por pirimidina, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para a prevenção ou tratamento de uma condição proliferativa
CN102014631A (zh) * 2008-03-03 2011-04-13 泰格尔医药科技公司 酪氨酸激酶抑制剂
JPWO2009157196A1 (ja) * 2008-06-25 2011-12-08 武田薬品工業株式会社 アミド化合物
GB0917934D0 (en) * 2009-10-13 2009-11-25 Syngenta Ltd Herbicidal compounds
CA2797719C (en) 2010-04-30 2019-11-26 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of usp1 deubiquitinating enzyme activity
CA2896731A1 (en) 2012-12-28 2014-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof
EP3760719A1 (en) 2013-11-18 2021-01-06 CRISPR Therapeutics AG Crispr-cas system materials and methods
JP2017510628A (ja) * 2014-03-13 2017-04-13 エージェンシー フォー サイエンス,テクノロジー アンド リサーチ 縮合ピリミジン系ヒドロキサメート誘導体
KR101766194B1 (ko) * 2015-08-07 2017-08-10 한국과학기술연구원 RET 키나아제 저해제인 신규 3-(이속사졸-3-일)-피라졸로[3,4-d]피리미딘-4-아민 화합물
US10189841B2 (en) * 2015-11-20 2019-01-29 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
BR112021010715A2 (pt) 2018-12-20 2021-11-16 Ksq Therapeutics Inc Pirazolopirimidinas substituídas e purinas substituídas e seu uso como inibidores de protease de processamento ubiquitina-específica 1 (usp1)
US20240182481A1 (en) 2021-02-15 2024-06-06 Tango Therapeutics, Inc. Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer

Similar Documents

Publication Publication Date Title
JPWO2020132269A5 (https=)
IL284050B1 (en) Modified pyrazolopyrimidines and modified purines and their use as 1 uso inhibitors
US20240239808A1 (en) Inhibiting ubiquitin-specific protease 1 (usp1)
Schenone et al. Biologically driven synthesis of pyrazolo [3, 4-d] pyrimidines as protein kinase inhibitors: an old scaffold as a new tool for medicinal chemistry and chemical biology studies
JP2022184886A5 (https=)
US11629147B2 (en) Triazolo-pyrimidine compounds and uses thereof
JP7723666B2 (ja) 環式化合物およびその使用方法
KR20190046921A (ko) 세포 대사 과정의 억제제
US8071581B2 (en) Triazolopyridazine protein kinase modulators
EP2084162B1 (en) Bicyclic triazoles as protein kinase modulators
JP2020505454A5 (https=)
JP2013523884A5 (https=)
RU2019120986A (ru) Фармацевтическая комбинация, содержащая ингибитор alk и ингибитор shp2
EP4237086A1 (en) Heterocyclic spiro compounds and methods of use
JP2015205905A (ja) JAKキナーゼの阻害剤としての5,7置換イミダゾ[1,2−c]ピリミジン
RU2012152548A (ru) Пиридоновые и азапиридоновые соединения и способы применения
JP2000159672A (ja) 硝酸誘発耐性の処置剤
US20230219965A1 (en) Nitrogen-containing fused bicyclic compounds and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors
US20240148732A1 (en) Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders
JPWO2021021986A5 (https=)
RU2021114721A (ru) Замещенные пиразолопиримидины и замещенные пурины и их применение в качестве ингибиторов убиквитин-специфической процессирующей протеазы 1 (usp1)
JPWO2022147092A5 (https=)
JPWO2021138498A5 (https=)
WO2025129135A2 (en) Compositions comprising usp1 inhibitors and methods of using the same
EA052528B1 (ru) Циклические соединения и способы их применения